Loading...
•
Dec 31, 2021
Schrodinger Q4 2021 Earnings Report
Reported strong fourth quarter results, highlighted by a 55 percent increase in software revenue compared to the same period last year.
Key Takeaways
Schrödinger reported a strong fourth quarter, with software revenue increasing by 55% compared to the fourth quarter of 2020. The company's total revenue for the quarter was $46.2 million, a 40% increase year-over-year. Schrödinger also provided its financial outlook for 2022 and outlined key strategic goals for 2022-2023.
Software revenue increased by 55% compared to the fourth quarter of 2020.
Total revenue increased by 40% year-over-year.
Gross profit increased by 39% year-over-year.
Company expects to initiate its first Phase 1 clinical study of its MALT1 inhibitor in patients with relapsed and resistant lymphoma later this year.
Schrodinger
Schrodinger
Forward Guidance
Schrödinger provided financial outlook for the fiscal year ending December 31, 2022.
Positive Outlook
- Total revenue expected to range from $161 million to $181 million, representing 17 percent to 31 percent growth over 2021
- Total software revenue expected to range from $126 million to $136 million, representing 11 percent to 20 percent growth over 2021
- Total drug discovery expected to range from $35 million to $45 million, representing 42 to 82 percent growth over 2021
- Operating expense growth is expected to be slightly lower than the 42 percent reported for the year ended December 31, 2021
- Software gross margin percentage is expected to be in the mid-70s